Loading
companiesCompany
Parexel
Parexel, of Durham, North Carolina, is a global contract research organisation owned by EQT and Goldman Sachs that runs early and late-phase oncology trials and sells regulatory consulting staffed by former FDA officials. Whether regulators moving into consulting sharpens trial design or blurs the line between regulator and industry is the question its model raises.
Overview
Parexel, based in Durham, North Carolina, is a global contract research organisation known for regulatory consulting staffed by former FDA officials and for its oncology trial operations. It is privately owned by EQT and Goldman Sachs and works across regulatory strategy, early-phase and late-phase oncology development. OnCo links it to contract research organisations. Whether the movement of regulators into consulting sharpens trial design or blurs the line between regulator and industry is the fair question its model raises. The CRO technology page carries the wider picture.
Similar pages
- CompanyFortrea
Shares Contract research organisations (CROs) and the tag supporting.
- CompanyCharles River Laboratories
Shares Contract research organisations (CROs) and the tag supporting.
- CompanySarah Cannon Research Institute
Shares Contract research organisations (CROs) and the tag supporting.
- CompanyIQVIA
Shares Contract research organisations (CROs) and the tag supporting.
- CompanyICON plc
Shares Contract research organisations (CROs) and the tag supporting.
- TechnologyClinical trial software (EDC, eCOA, CTMS, RTSM)
Shares Contract research organisations (CROs) and the tag supporting.
- TechnologyImaging core labs and central review
Shares Contract research organisations (CROs) and the tag supporting.
- CompanyThermo Fisher Scientific
Shares Contract research organisations (CROs) and the tag supporting.
fronts
technologies
trials
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal AdenocarcinomaA Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid TumorsBCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC ParticipantsRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)